

Validation data for Anti-CoV2RBD-c2-mIgG2a (clone B38)

<https://www.invivogen.com/sars2-spike-b38-mab>

For research use only

Version 21D08-NJ

Anti-CoV2RBD-c2-mIgG2a is a recombinant monoclonal antibody (mAb) featuring the variable region of the SARS-CoV-2 spike mAb (clone B38), which specifically targets the SARS-CoV-2 Spike receptor-binding domain (RBD), and the constant region of the mouse IgG2a (mIgG2a) isotype. The binding of the antibody has been validated by ELISA using a coated Spike-RBD-His fusion peptide (Figure 1).

Binding of Anti-CoV2RBD-c2-mIgG2a to SARS-CoV-2 spike RBD by ELISA




Figure 1: Validation of binding to SARS-CoV-2 RBD by ELISA. SARS-CoV-2 Spike-RBD-His fusion peptide (5 µg/ml) was coated onto ELISA plates overnight. A serial dilution of Anti-CoV2RBD-c2-mIgG2a (red curve) or Anti-β-Gal-mIgG2a (control antibody; grey curve) was added to the pre-coated plate and incubated for 1 hour. Subsequently, binding was detected with a HRP-labelled anti-mIgG2a antibody (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride). Absorbance was read at 490 nm.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3-622-34-80
E-mail: info@invivogen.com